This study investigated the feasibility of targeting the free, unbound forms of prostate-specific antigen (fPSA) for in vivo imaging of prostate adenocarcinomas (PCa), as PSA is produced and secreted at abundance during every clinical stage and grade of PCa, including castrationresistant disease. We injected 125
I-labeled monoclonal antibody PSA30 (specific for an epitope uniquely accessible on fPSA alone) intravenously in male nude mice carrying subcutaneous xenografts of LNCaP tumors (n=36). Mice were sacrificed over a time course from 4 hours to 13 days after injecting 125 I-labeled PSA30. Tissue uptake of 125 I-PSA30 at 48
and 168 hours after intravenous injection was compared with two clinically used positron emission tomography radiopharmaceuticals, 18 F-fluoro-deoxy-glucose ( 18 F-FDG) or 18 Fcholine, in cryosections using Digital AutoRadiography (DAR) and also compared with immunohistochemical staining of PSA and histopathology. On DAR, the areas with high 125 I-PSA30 uptake corresponded mainly to morphologically intact and PSA-producing LNCaP cells, but did not associate with the areas of high uptake of either 18 F-FDG or 18 F-choline.
Introduction
Imaging modalities used for the detection and monitoring of extraprostatic or locally advanced growth of prostate adenocarcinomas (PCas) are constantly developing and improving. 1,2 Apart from morphological imaging, such as ultrasonography, computed tomography and magnetic resonance imaging (MRI), molecular imaging like positron emission tomography (PET) imaging of metabolic probes, such as 18 F-fluoro-deoxy-glucose ( 18 F-FDG) and 18 F-or 11 C-labeled choline, has shown to improve detection of both locally advanced and metastatic disease. 18 FDG measures glucose metabolism, which is upregulated in many cancers. However, most primary PCa tumors exhibit low, if any, 18 FDG uptake. [3] [4] [5] [6] On the other hand, choline kinase is frequently over-expressed in PCa 7, 8 and as 18 F-or 11 Clabeled choline derivatives are trapped inside the cell by choline kinase, information is provided about the rate of lipid synthesis. [9] [10] [11] [12] [13] However, there is also uptake of both 18 F-and 11 C-labeled choline in benign disease conditions as well. is too large to allow for renal clearance and is eliminated very slowly, possibly via uptake by hepatocytes. [20] [21] [22] [23] [24] Prior attempts to target PSA for in vivo imaging of PCa metastases investigated human subjects with advanced disseminated stages of the disease 25 ; only one study was based on mice xenografts. 26 Imaging of PSA was mostly successful in these studies; however, the image quality was poor due to high liver uptake and high nonspecific background activity. 27 Notably, the design of these studies was not based on the subsequently reported investigations
showing that PSA in the extracellular fluids occurs in many different molecular forms with distinctly different rates and mechanisms of clearance. 17, 20, 28, 29 Also, the antibodies used in prior studies to detect PSA in vivo were polyclonal; hence, they could cross-react with other antigens and did not discriminate fPSA from cPSA. This feat was not possible until the early 1990s when it was first reported on the discovery of fPSA and the development of monoclonal antibodies specific to antigenic epitopes uniquely accessible on fPSA alone, but unable to detect PSA linked to protease inhibitors, such as ACT. 17, 19, 30 Therefore, as no prior study explored the feasibility of using fPSA as a target for in vivo imaging, we now investigated whether a monoclonal antibody (mAb) specific for fPSA in animals chosen for DAR analysis. From these tests, we were able to distinguish different patterns of uptake in tumor sections by isotope separation using DAR images corresponding to histology and immunohistochemistry (IHC) of adjacent sections.
Materials and Methods

The PSA30 mAb
To assess whether it may be feasible to use human fPSA as a target for the imaging of PCa cells in vivo, we used the PSA30 anti-fPSA mouse mAb, which has an IgG1 isotype as previously described. 31 Comprehensive epitope mapping studies have demonstrated that PSA30 has very similar binding characteristics to some of the originally developed mouse mAbs (e.g. 5A10) specific for fPSA alone, 17, 19, 30, 32 and PSA30 recognizes an epitope covered by ACT that is accessible only on fPSA.
32, 33
Radiolabeling
The PSA30 antibody was labeled with 125 I (PerkinElmer), using the Iodogen method. Briefly, a coated test tube with 150 µg 1,3,4,6-tetrachloro-3α,6α-diphenyl glycoluril was used for labeling of 200 µg PSA30. After the mixture had been incubated for 15 minutes at room temperature, low-molecular-weight components were removed by gel filtration (PD-10 column; GE Healthcare). The radiochemical purity was 95% after gel filtration. 
Tumor section imaging
LNCaP-tumor-bearing mice (n=36) were administered 125 I-labeled PSA30 formulations (~10 was used to image the distribution of radioactivity within the thicker sections. Differences in both emission spectra and rate of decay were used to produce separate images of each radionuclide in animals injected with more than one radionuclide, in this case, 125 I and 18 F.
IHC and histopathology
To study PSA expression, 20-µm tumor cryosections (frozen and secured as described previously) were examined using IHC. The immunoreactivity against PSA was visualized by use of the DAKO EnVision Flex/HRP system kit (Dako Corporation). Adjacent tumor sections were also stained with hematoxylin (nuclei stain) and eosin (cytoplasmic stain) (H&E) and the general morphology analyzed under a standard transillumination microscope.
With H&E staining, viable regions of the tumor sections and necrotic areas were stained. As a positive control, LNCaP tumor sections were incubated with PSA mAb 2E9 17 at a dilution of 1:1000 and visualized as described previously. As a negative control, tumor section from a mouse that received an intravenous injection of PSA30 was visualized without incubation of a secondary antibody, but including all other steps of IHC. The stained sections were scanned using a Carl Zeiss MIRAX Scan microscope scanner and viewed with the MIRAX Viewer software (Carl Zeiss Imaging Solutions GmbH).
Biodistribution study
Biodistribution studies were conducted in both nontumor-bearing mice (n=14) and in LNCaPtumor-bearing mice (n=34). All mice were randomized before the study and administered 1 and 2) . Notably, as the mice were allowed free movement after the 18 F-FDG injection, as expected, the DAR images showed a high degree of 18 F-FDG uptake in muscle (Fig. 2 , red square) that was left on the tumor after it was removed from the mouse; this uptake is not seen on the 125 I-PSA30 DAR picture of the same tumor.
Results
DAR, IHC and histopathology
Except for areas of necrosis, there was close similarity between the distribution of PSA staining by IHC and high activity of 125 I-PSA30 uptake on DAR, thus confirming that the radioactivity found in tumor sections by DAR was strongly associated with evidence of PSA staining by IHC and not a consequence of the presence of free iodine or other metabolites.
Biodistribution in nontumor-bearing mice
A decrease of activity after injection was noted in all organs (except the thyroid), and blood from the first measurement after intravenous injection of the 125 I-PSA30 formulations to the last (312 hours) (see Table 1A ). As shown in Figure 3A , the decrease in %IA/g during the first 24 hours ranged from 55% to 83% in liver, kidney, and blood (Fig. 3A) . The highest %IA/g was found in organs with large residual blood content. 35 The O/Bl ratios in highly vascularized organs (see Table 2 ) remained largely unchanged over time, indicating that no unspecific 125 I-PSA30 binding occurred, which is in accordance with the fact that PSA is not expressed in nonprimate species, such as mice and rodents. 36 However, thyroid levels increased from 6 to 168 hours postinjection.
Biodistribution in LNCaP-tumor-bearing mice
Similar to our findings in nontumor-bearing mice, highly vascularized organs initially showed high activity levels that rapidly decreased from the first measurement after intravenous injection of 125 I-PSA30 (see Table 1B ; Fig. 3B ). Similarly, the O/Bl ratios remained largely unchanged over time in these organs (see Table 2 ). LNCaP tumors had higher uptake compared with other investigated organs at most time points and peaked (4.32 %IA/g) at 24
hours after intravenous injection of 125 I-PSA30 formulations. By contrast to all other organs showing a decrease of activity, LNCaP tumors showed a marked increase of activity (by 32%) during the first 24 hours after injection (Fig. 3B) . Tumor-specific accumulation of 125 I-PSA30
was further demonstrated by a markedly divergent O/Bl ratio (see Table 2 ). In comparison to nontumor-bearing mice, thyroid accumulation was greatly augmented. 125 I-PSA30 mAb uptake in LNCaP tumors peaks at 24 hours postinjection (Fig. 3B) , with a subsequent sharp decrease in tumor uptake noted by 72 hours postinjection. Importantly, at this same time point, there is a sharp increase in thyroid uptake. This inverse correlation is a likely indicator that a dehalogenation effect has occurred.
Discussion
The use of PSA as an in vivo imaging target was previously investigated 15-20 years ago, but abandoned as an imaging target due to high activity in blood and large uptake in bloodbearing organs. 25, 26, 37 However, advances in the field of antibody manufacturing combined with better understanding of the structure-function relationship of PSA and its interaction with protease inhibitors prompted us to hypothesize that the targeting of fPSA, rather than complexed or total PSA, could be present at high abundance in close proximity to its local site of production. This could provide another theoretical advantage as fPSA has been shown to clear rapidly (t 1/2 of 12-18 hours) from the extracellular compartments by glomerular filtration in the kidneys, 20, 23, 24 as opposed to the PSA-ACT complex which is too large (≈90 kDa) to allow for renal clearance. Hence, the elimination rate of PSA-ACT (and also total PSA) is slow with possible limited capacity. To the best of our knowledge, the specific targeting of fPSA for in vivo imaging has not previously been reported. The targeting of fPSA may also be unique due to that it represents a highly abundant secretory protein, 38 as opposed to current strategies to target extracellular domains of integral plasma membrane proteins, such as the prostate-specific membrane antigen. 39 The diagnostic information contributed by a fPSA targeting strategy is likely to be influenced by mutations, other genetic rearrangements, or therapies affecting the functionality of the androgen receptor (AR) as production and secretion of fPSA is regulated by androgens and AR function. 15, 40, 41 In the present study, the specific targeting of fPSA was investigated by using PSA30, an IgG1 that is specific for an epitope region uniquely available on fPSA alone. 30, 32 We successfully employed labeling with 125 I and evaluated targeting by DAR and biodistribution studies in both LNCaP-tumor-bearing mice and nontumor-bearing animals.
The uptake of 125 I-PSA30 on DAR was compared with the uptake of co-injected 18 F-labeled metabolic probes (FDG and choline).
Our results show that 125 I-PSA30 can effectively target fPSA in LNCaP-based xenograft mice.
DAR revealed a pattern of uptake associated to PSA expression. However, we also noted bright hotspots in necrotic areas where the 125 I-PSA30 uptake in these necrotic areas did not correspond to PSA expression, as revealed on IHC.
We also evaluated 125 I-PSA30 mAb uptake in relation to 18 F-FDG or 18 F-choline in the same animal and found that FDG uptake, a measure of cellular metabolic activity (Fig. 2) , and choline uptake, a measure of increased cellular proliferation (Fig. 1B) Our DAR data were supplemented with biodistribution studies (see Tables 1A, B) . Based on these data, we demonstrate that the PSA30 mAb uptake in excised tumors peaked at 24 hours postintravenous injection, and is retained in tumor as compared to normal tissues (see Table   1B ). The relatively low T/O ratios (see Table 3 Notable is the observed rapid decrease of activity from the liver and kidneys between 4 hours and 13 days (both -95%), illustrating the antibody is not retained for long periods of time in the organs. The size of both IgG1 and IgG1 bound to PSA prevents it from renal filtration.
Thus, the activity observed in the kidney most likely reflects free iodine that has re-entered the circulation after the antibody has been digested in the liver or due to free iodine caused by dehalogenation.
Conclusions
Our results suggest that it is feasible to image the free, unbound forms of PSA using a radiolabeled mAb specific for fPSA, and thus the development of a means to evaluate fPSA in vivo as an imaging target in PCa should be continued. To achieve higher T/O and T/Bl ratios we now aim to increase the antibody dose administered, test alternative labeling techniques and radionuclides, as well as fragmented antibodies. 
